Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Experts are anticipating strong growth driven by the strong demand of Lilly's blockbuster drugs, particularly recent launches. However, there are also concerns about potential headwinds from regulatory scrutiny,